Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. interventional cardiologists
Show results for
Products
Services
Software
Training
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Interventional Cardiologists Articles & Analysis

49 news found

An Easy, Predictable, and Simpler Way to Embolize Tumors

An Easy, Predictable, and Simpler Way to Embolize Tumors

Instylla is now enrolling patients in a clinical trial for the world’s first hydrogel-based liquid embolic intended for the treatment of hypervascular tumors. A second initial application for its Embrace embolic therapy is hemorrhage control, where the product offers advantages in terms of simplicity, speed, and safety. Amar Sawhney and his teams, it seems, can make medical hydrogels do ...

ByInstylla, Inc.


Osso VR and American College of Cardiology to Develop Immersive Training for Cardiovascular Professionals

Osso VR and American College of Cardiology to Develop Immersive Training for Cardiovascular Professionals

Osso VR, now the largest and fastest-growing virtual reality (VR) company in healthcare, and the American College of Cardiology (ACC), a global nonprofit dedicated to transforming cardiovascular care, today announced a new collaboration to develop an immersive, VR-enabled training program for cardiovascular professionals. The collaboration builds upon the ACC’s long tradition of ...

ByOsso VR, Inc.


1st Successful Heart Tumor Removal Without Open Heart Surgery

1st Successful Heart Tumor Removal Without Open Heart Surgery

A cardiac puzzle This procedure, like the one before it, was conducted with the assistance of Jacob Dutcher, MD, an interventional cardiologist and director of the Structural Heart Program at CentraCare Heart & Vascular Center, and EchoPixel’s chief medical officer. ...

ByEchoPixel, Inc.


Shockwave Medical Initiates All-Female Coronary IVL Study

Shockwave Medical Initiates All-Female Coronary IVL Study

EMPOWER CAD is the First Prospective, Female-Only Study of Coronary Interventions Study Seeks to Confirm Benefits of Shockwave’s Coronary IVL in Females Who Historically Have Suffered Less Favorable Clinical Outcomes than Male Patients with Traditional Therapies Shockwave Medical, Inc. ...

ByShockwave Medical Inc.


Inari Medical Announces Results from the Fully Enrolled 800-patient US Cohort of the FlowTriever FLASH Registry

Inari Medical Announces Results from the Fully Enrolled 800-patient US Cohort of the FlowTriever FLASH Registry

The data was presented during a Late-Breaking Clinical Trial session at the 2022 TCT (Transcatheter Cardiovascular Therapeutics) conference on September 18th by Principal Investigator (PI), Catalin Toma, MD, an Interventional Cardiologist at University of Pittsburgh Medical Center (UPMC). The data was also simultaneously published in EuroIntervention, the ...

ByInari Medical


Belgian scale-up Oncomfort raises €10 million in Series A funding co-led by Debiopharm and Crédit Mutuel Innovation

Belgian scale-up Oncomfort raises €10 million in Series A funding co-led by Debiopharm and Crédit Mutuel Innovation

Oncomfort, the Belgian inventor of and leader in Digital Sedation - a new method for relieving patients’ pain and anxiety without medication - today announces the completion of a €10 million Series A funding round co-led by two prominent institutional investors: Debiopharm and Crédit Mutuel Innovation. Oncomfort plans to use this investment to further develop its innovative ...

ByOncomfort


Puzzle Medical Announces the Successful Completion of its First-in-Human Study with its ModulHeart

Puzzle Medical Announces the Successful Completion of its First-in-Human Study with its ModulHeart

Four patients had ModulHeart deployed to provide circulatory support while undergoing high-risk percutaneous coronary intervention (PCI) procedures. All patients experienced improvements in cardiac and kidney function. ...

ByPuzzle Medical Devices Inc.


reSept ASD Occluder implanted in EU for the first time

reSept ASD Occluder implanted in EU for the first time

Professor Jean-Benoît Thambo, head of the department of pediatric and congenital cardiology at the Bordeaux University Hospital, said to France3 how “these prostheses are the first phase of the medicine of tomorrow, a medicine that opts for material adapted to the body, biological”. As interventional cardiologist Zakaria Jalal explained to ...

ByatHeart Medical


Arterius Welcomes New Clinical Advisers

Arterius Welcomes New Clinical Advisers

Arterius are pleased to welcome Prof. Patrick Serruys and Dr. Yoshi Onuma to our clinical advisory board. Prof. Serruys (Imperial College, London) will become chair of the clinical advisory board, also now featuring Dr. Onuma (Cardialysis, Netherlands) and Dr. Rasha Al-Lamee (Imperial College, London). Prof. Patrick W. Serruys is is a professor of Interventional Cardiology at the ...

ByArterius Limited


Shockwave IVL Coronary Studies Demonstrate Excellent PCI Outcomes in Both Women and Men at One Year

Shockwave IVL Coronary Studies Demonstrate Excellent PCI Outcomes in Both Women and Men at One Year

The one-year results from the Disrupt CAD clinical program were presented at the 2022 Scientific Sessions of the Society for Cardiovascular Angiography & Interventions (SCAI). Unlike previous reports with atherectomy that have shown worse angiographic complications in women versus men,i a pooled analysis of the Disrupt CAD III & IV studies showed that IVL was equally ...

ByShockwave Medical Inc.


Robocath achieves positive results in R-Evolution multicenter European clinical study on robotic coronary angioplasty

Robocath achieves positive results in R-Evolution multicenter European clinical study on robotic coronary angioplasty

The study, which included 62 patients across six European centers, shows that coronary angioplasties using the R-One™ robot are safe and effective for patients, while also improving the working conditions for the interventional cardiologist by drastically reducing exposure to X-rays. The results will be presented in detail at a second dedicated session ...

ByRobocath


BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed

The DSMB consists of two world renowned cardiologists with experience in heart failure and interventional cardiology, as well as a world-renowned biostatistician with considerable experience evaluating trial data for chronic diseases, including heart failure. ...

ByBiocardia, Inc.


Anteris reports successful interim results for the first-in-human trial for DurAVR

Anteris reports successful interim results for the first-in-human trial for DurAVR

The system also allowed for excellent commissural alignment; a significant patient benefit if future coronary intervention were required. A 20% increase from baseline in 6 min walk test (a measure of patient exercise tolerance). ...

ByAnteris Technologies Limited


Robocath concludes first European clinical study to demonstrate safety and efficacy of robotic coronary angioplasty performed with R-One

Robocath concludes first European clinical study to demonstrate safety and efficacy of robotic coronary angioplasty performed with R-One

Full results of the study are due in May 2022 and will be presented at the EuroPCR conference. Prof. Eric Durand, interventional cardiologist at the Rouen University Hospital center and joint principal investigator for the study, explained: “I feel honored to have had the chance to be joint principal investigator of the R-Evolution clinical study. ...

ByRobocath


Robocath successfully completes first robotic coronary angioplasty with R-One in China

Robocath successfully completes first robotic coronary angioplasty with R-One in China

The procedure took place at the 301 Hospital in Beijing on November 24; performed by Dr. Yundai Chen, a renowned interventional cardiologist and author of several scientific publications. ...

ByRobocath


InspireMD Announces Publication of 12-Month Results of CGuard™ EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions

InspireMD Announces Publication of 12-Month Results of CGuard™ EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions

InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced that results from the investigator-initiated SIBERIA randomized clinical trial of CGuard EPS, that evaluated the peri-procedural and 30-day silent brain infarcts associated with the use of its ...

ByInspireMD Inc.


BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia

BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia

The first patient was treated with the investigational CardiAMP autologous cell therapy at the University of Wisconsin in Madison, by Interventional Cardiologist and Associate Professor of Medicine Amish Raval, M.D., supported by Peiman Hematti, M.D., Bone Marrow Transplantation Hematologist and Professor of Medicine. ...

ByBiocardia, Inc.


DurAVR accepted into TCT innovation session

DurAVR accepted into TCT innovation session

Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company) announces its submission at this year’s Transcatheter Cardiovascular Therapeutics (TCT) conference at Orlando, Florida, United States was accepted into the innovation session. The TCT conference, running from November 4 to 6, is the largest and most prestigious Interventional cardiology meeting held each year and will return to ...

ByAnteris Technologies Limited


CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR Antithrombotic Removal System During Urgent Cardiothoracic Surgery

CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR Antithrombotic Removal System During Urgent Cardiothoracic Surgery

Michael Gibson and an Executive Committee comprised of world–renowned cardiac surgeons, interventional cardiologists, and thrombosis/hemostasis experts. Trial start-up activities are underway and we expect the study to start in the first quarter of ...

ByCytoSorbents Corporation


World’s First Watchman ProcedurewWithout the Use of Contrast Dye

World’s First Watchman ProcedurewWithout the Use of Contrast Dye

Rather than relying on contrast dye and X-ray based imaging to help guide the implant placement, Jacob Dutcher, MD, an interventional cardiologist and director of the Structural Heart Program at CentraCare Heart & Vascular Center, performed the procedure using ultrasound-based 4D holographic imaging, which provides an image so clear that potentially harmful ...

ByEchoPixel, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT